

## **EBCTCG collaborators, listed alphabetically by institution and then alphabetically by name**

*Patient representatives (past & present)*—E Bergsten-Nordström, P Halpin-Murphy, T Spanic.

*AARTM 048/13/2000 Multicentre Study Group, Spain*—J A Alberro, B Ballester, P Deulofeu, R Fábregas, M Fraile, J M Gubern, J Janer, A Moral, J L de Pablo, G Peñalva, P Puig, M Ramos, R Rojo, P Santesteban, C Serra, M Solà, L Solarnau, J Solsona, E Veloso, S Vidal.

*ACETBC, Tokyo, Japan*—O Abe, R Abe, K Enomoto, K Kikuchi, H Koyama, H Masuda, Y Nomura, Y Ohashi, K Sakai, K Sugimachi, M Toi, T Tominaga, J Uchino, M Yoshida.

*Addenbrooke's Hospital, Cambridge, UK*—C E Coles, J L Haybittle.

*Alliance for Clinical Trials in Oncology, USA*—K V Ballman, L A Carey, A DeMichele, M Gnant, E Mayer, A Wolff.

*AGO Breast Study Group (AGO-B), Germany*—V Möbus.

*American College of Surgeons Oncology Group (ACOSOG), USA*—A U Buzdar, K K Hunt, V J Suman.

*Anglo-Celtic Cooperative Oncology Group, UK*—J Crown, C F Leonard, J Mansi.

*ARCOSEIN Group, France*—G Calais, P Garaud.

*Association Européenne de Recherche en Oncologie (AERO), France*—C Delbaldo, P Piedbois, E Quinaux.

*ATLAS Trial Collaborative Study Group, Oxford, UK*—J Braybrooke, C Davies, R Gray, H C Pan, R Peto, J Sayer.

*Auckland Breast Cancer Study Group, New Zealand*—V J Harvey, I M Holdaway, R G Kay, B H Mason.

*Austrian Breast Cancer Study Group, Vienna, Austria*—M Balic, R Bartsch, C Fesl, F Fitzal, H Fohler, M Gnant, R Greil, R Jakesz, C Marth, B Mlineritsch, G Pfeiler, C F Singer, L Sölkner, G G Steger, H Stöger.

*Beatson Oncology Centre, Glasgow, UK*—P Canney, H M A Yosef.

*Belfast City Hospital, UK*—S McIntosh.

*Belgian Adjuvant Breast Cancer Project, Liège, Belgium*—C Focan.

*Bergen Breast Cancer Group, Norway*—H P Eikesdal, P E Lønning.

*Berlin-Buch Akademie der Wissenschaften, Germany*—U Peek.

*Birmingham General Hospital, UK*—G D Oates, J Powell.

*Bordeaux Institut Bergonié, France*—M Durand, L Mauriac.

*Bordet Institute, Brussels, Belgium*—J Crown, A Di Leo, S Dolci, V van Dooren, D Larsimont, J M Nogaret, C Philippson, M J Piccart.

*Bradford Royal Infirmary, UK*—M B Masood, D Parker, J J Price.

*Breast Cancer Now Toby Robins Research Centre, Institute of Cancer Research, London, UK*—A Tutt.

*Breast Cancer Study Group of the Comprehensive Cancer Centre, Limburg (BOOG), Netherlands*—P S G J Hupperets.

*Breast Cancer Trials (formerly ANZBCTG), Newcastle, Australia*—B H Chua, J F Forbes, P A Francis, N Wilcken, N Zdenowski.

*British Association of Surgical Oncology BASO II Trialists, London, UK*—T Bates, R W Blamey, U Chetty, I O Ellis, E Mallon, D A L Morgan, J Patnick, S Pinder.

*British Columbia Cancer Agency, Vancouver, Canada*—C Lohrisch, A Nichol.

*Canadian Cancer Trials Group, Kingston, Ontario, Canada*—J M S Bartlett, V H Bramwell, B E Chen, S K L Chia, K Gelmon, P Goodwin, P E Goss, M N Levine, W Parulekar, J L Pater, K I Pritchard, E Rakovitch, L E Shepherd, D Tu, T Whelan.

*Cancer and Leukemia Group B, Washington DC, USA*—D Berry, G Broadwater, C Cirrincione, H Muss, L Norton, L N Shulman, R B Weiss.

*Cancer Care Ontario, Canada*—H T Abu-Zahra.

*Cancer Research Centre of the Russian Academy of Medical Sciences, Moscow, Russia*—A Karpov, S M Portnoj.

*Cancer Research UK Clinical Trials Unit (CRCTU), NCRI, Birmingham, UK*—S Bowden, I Fernando, M Lee, C Poole, D Rea, D Spooner.

*Cardiff Trialists Group, UK*—P J Barrett-Lee, R E Mansel, I J Monypenny.  
*Case Western Reserve University, Cleveland, OH, USA*—N H Gordon.  
*Central Oncology Group, Milwaukee, WI, USA*—H L Davis.  
*Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, UK*—J Cuzick, I Sestak.  
*Centre Léon-Bérard, Lyon, France*—Y Lehingue, P Romestaing.  
*Centre Paul Lamarque, Montpellier, France*—J B Dubois.  
*Centre Régional François Baclesse, Caen, France*—T Delozier, B Griffon, J Mace Lesec'h.  
*Centro Oncologico, Trieste, Italy*—G Mustacchi.  
*Charles University in Prague, First Faculty of Medicine, Department of Oncology of the First Faculty of Medicine and General Teaching Hospital, Czech Republic*—L Petruzalka, O Pribylova.  
*Cheltenham General Hospital, UK*—J R Owen.  
*Chemo NO Trial Group, Germany*—N Harbeck, F Jänicke, C Meisner, M Schmitt, C Thomssen.  
*Chicago University, IL, USA*—P Meier.  
*Chinese Academy of Medical Sciences, Beijing, People's Republic of China (in collaboration with the Oxford Nuffield Department of Population Health (NDPH))*—Y Shan, Y F Shao, X Wang, B Xu, D B Zhao (NDPH: Z M Chen, H C Pan).  
*Christie Hospital and Holt Radium Institute, Manchester, UK*—A Howell, R Swindell.  
*Clinical Trials Research Unit (CTRU), University of Leeds, UK*—G Booth, J Brown, J Emmerson.  
*Coimbra Instituto de Oncologia, Portugal*—J Albano, C F de Oliveira, H Gervásio, J Gordilho.  
*Cookridge Hospital, Leeds, UK*—D Dodwell.  
*Copenhagen Breast Cancer Trials, Copenhagen, Denmark*—B Ejlertsen, M-B Jensen, H Mouridsen.  
*Dana-Farber Cancer Institute, Boston, MA, USA*—R S Gelman, J R Harris, C Henderson, C L Shapiro, E Winer.  
*Danish Breast Cancer Cooperative Group, Copenhagen, Denmark*—P Christiansen, B Ejlertsen, M Ewertz, M-B Jensen, A Knoop, H T Mouridsen (deceased), B V Offersen, T F Tvedskov.  
*Düsseldorf University, Germany*—T Fehm, H J Trampisch.  
*Dutch Breast Cancer Trialists' Group (BOOG), Netherlands*—E J Blok, S Geurts, J R Kroep, G J Liefers, S Linn, E Meershoek-Klein Kranenbarg, H M Oosterkamp, P Peer, E J Rutgers, V Tjan-Heijnen, C J H van de Velde, I E G van Hellemond, E van Leeuwen-Stok, E van Werkhoven.  
*Dutch Working Party for Autologous Bone Marrow Transplant in Solid Tumours, Amsterdam & Groningen, Netherlands*—O Dalesio, E G E de Vries, S Rodenhuis, H van Tinteren .  
*Eastern Cooperative Oncology Group, Boston, MA, USA*—R L Comis, N E Davidson, R Gray, N Robert, G Sledge, L J Solin, J A Sparano, D C Tormey, W Wood.  
*Edinburgh Breast Unit, UK*—D Cameron, U Chetty, J M Dixon, P Forrest, W Jack, I Kunkler.  
*Elim Hospital, Hamburg, Germany*—J Rossbach.  
*Erasmus MC/Daniel den Hoed Cancer Center, Rotterdam, Netherlands*—J G M Klijn, A D Treurniet-Donker, W L J van Putten.  
*European Cooperative Trial in Operable Breast Cancer (ECTO)*—W Eiermann, L Gianni, P Valagussa.  
*European Institute of Oncology, Milan, Italy*—V Galimberti, N Rotmensz, U Veronesi, G Viale.  
*European Organization for Research and Treatment of Cancer, Brussels, Belgium*—H Bartelink, N Bijker, J Bogaerts, H Bonnefoi, F Cardoso, T Cufer, J P Julien, M Piccart, C Poncet, P M Poortmans, E Rutgers, C J H van de Velde.  
*Evanston Hospital, IL, USA*—M P Cunningham.  
*FACE trial (sponsored by Novartis Pharmaceuticals)*—Smith I, R De Boer, D Amadori, B Eijertsen, M Gnant, W Jonat, K I Pritchard, J O'Shaughnessy.  
*Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) Breast Group, France*—T Delozier, M Spielman, J Mace Lesec'h.  
*Finnish Breast Cancer Group, Finland*—R Huovinen, H Joensuu.  
*Fondazione Maugeri Pavia, Italy*—A Costa.  
*Fondazione Michelangelo, Milan, Italy*—G Bonadonna, L Gianni, P Valagussa.

*Fox Chase Cancer Center, Philadelphia, PA, USA*—L J Goldstein.  
*Fortis Memorial Research Institute, Haryana, India*—V Raina.  
*French Adjuvant Study Group (GFEA), Guyancourt, France*—J Bonnetterre, P Fargeot, P Fumoleau, P Kerbrat, E Luporsi, M Namer.  
*Fudan University Shanghai Cancer Center, Shanghai, China*—Z M Shao, K D Yu.  
*Gasthuis Zusters Antwerpen, Belgium*—R Salgado.  
*GEICAM, Spanish Breast Cancer Group, Spain*—E Carrasco, J A Garcia-Saenz, M Martin, M A Segui.  
*German Adjuvant Breast Group (GABG), Frankfurt, Germany*—W Eiermann, J Hilfrich, W Jonat, M Kaufmann, R Kreienberg, M Schumacher.  
*German Breast Cancer Study Group (BMFT), Freiburg, Germany*—G Bastert, H Rauschecker, R Sauer, W Sauerbrei, A Schauer, M Schumacher.  
*German Breast Group (GBG), Neu-Isenburg, Germany*—J U Blohmer, S D Costa, H Eidtmann, B Gerber, C Jackisch, S Kümmel, S Loibl, V Nekljudova, G von Minckwitz.  
*Ghent University Hospital, Belgium*—A de Schryver, L Vakaet.  
*GIVIO Interdisciplinary Group for Cancer Care Evaluation, Chieti, Italy*—M Belfiglio, A Nicolucci, F Pellegrini, M C Pirozzoli, M Sacco, M Valentini.  
*Glasgow Victoria Infirmary, UK*—C S McArdle, D C Smith, S Stallard.  
*Groote Schuur Hospital, Cape Town, South Africa*—D M Dent, C A Gudgeon, A Hacking, E Murray, E Panieri, ID Werner.  
*Gruppo Interdisciplinare Veneto di Oncologia Mammaria (GIVOM), Italy*—G L De Salvo, P Del Bianco, G Zavagno.  
*Grupo Oncológico Cooperativo del Sur (GOCS), Argentina*—B Leone, C T Vallejo, A Zwenger.  
*Gruppo Oncologico Clinico Cooperativo del Nord Est, Aviano, Italy*—E Galligioni.  
*Gruppo Oncologico Dell'Italia Meridionale (GOIM), Rome, Italy*—M Lopez.  
*Guadalajara Hospital de 20 Noviembre, Mexico*—A Erazo, J Y Medina.  
*Gunma University, Japan*—J Horiguchi, H Takei.  
*Guy's Hospital, London, UK*—I S Fentiman, J L Hayward, R D Rubens, D Skilton.  
*Heidelberg University I, Germany*—H Scheurlen.  
*Heidelberg University II, Germany*—M Kaufmann, H C Sohn.  
*Helios Klinikum Berlin-Buch, Germany*—M Untch.  
*Hellenic Breast Surgeons Society, Greece*—U Dafni, C Markopoulos.  
*Hellenic Cooperative Oncology Group, Athens, Greece*—G Fountzilas, G-A Koliou.  
*Hellenic Oncology Research Group, Greece*—D Mavroudis.  
*Helsinki Deaconess Medical Centre, Finland*—P Klefstrom.  
*Helsinki University, Finland*—C Blomqvist, T Saarto.  
*Herceptin-Adjuvant (HERA)/Breast International Group (BIG)*—D Cameron, E de Azambuja, R Gelber, M Piccart, M Regan.  
*Hospital del Mar, Barcelona, Spain*—M Gallen.  
*Humanitas Cancer Center, Milan, Italy*—G Canavese, C Tinterri.  
*Innsbruck University, Austria*—R Margreiter.  
*Institut Claudius Regaud, Toulouse, France*—B de Lafontan, J Mihura, H Roché.  
*Institut Curie, Paris, France*—B Asselain, R J Salmon, J R Vilcoq.  
*Institut Curie - Hôpital René Huguenin, Paris, St Cloud, France*—E Brain, B de La Lande, E Mouret-Fourme.  
*Institut Gustave-Roussy, Paris, France*—F André, R Arriagada, S Delaloge, C Hill, S Koscielny, S Michiels, P Pélissier, C Rubino.  
*Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTS, NCR), UK*—R A'Hern, J Bliss, P Ellis, L Kilburn, J R Yarnold.  
*Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, GEICAM, CIBERONC, Madrid, Spain*—M Martin.  
*Instituto Nacional de Cancer, Brazil*—J Bines, R M B Sarmiento.

*Integraal Kankercentrum, Amsterdam, Netherlands*—J Benraadt, M Kooi, A O van de Velde, J A van Dongen, J B Vermorcken.

*International Atomic Energy Agency (IAEA), Vienna, Austria*—G W Jones, E Rosenblatt, E Zubizarreta.

*International Breast Cancer Study Group (IBCSG), Bern, Switzerland*—M Castiglione, A Coates, M Colleoni, J Collins, J Forbes, R D Gelber, A Goldhirsch, J Lindtner, O Pagani, K N Price, M M Regan, C M Rudenstam, H J Senn, B Thuerlimann.

*International Collaborative Cancer Group, London, UK*—J M Bliss, C E D Chilvers, R C Coombes, M Espie, E Hall, L Kilburn, M Marty.

*International Drug Development Institute, Louvain-la-Neuve, Belgium*—M Buyse.

*International TABLE Study Group, Berlin, Germany*—K Possinger, P Schmid, M Untch, D Wallwiener.

*ISD Cancer Clinical Trials Team (incorporating the former Scottish Cancer Therapy Network), Edinburgh, UK*—L Foster, W D George, H J Stewart, P Stroner.

*Israel NSABC, Tel Aviv, Israel*—R Borovik, H Hayat, M J Inbar, T Peretz, E Robinson.

*Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy*—G Bonadonna, C Brambilla, T Camerini, F Formelli, G Martelli, M G Di Mauro, A Rossi, P Valagussa.

*Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy*—C Gallo, F Perrone.

*Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy*—D Amadori, F Boccardo, O Nanni, A Rubagotti, E Scarpi.

*Italian Cooperative Chemo-Radio-Surgical Group, Bologna, Italy*—A Martoni, F Pannuti.

*Italian Oncology Group for Clinical Research (GOIRC), Parma, Italy*—R Camisa, A Musolino, R Passalacqua.

*Japan Breast Cancer Research Group (JBCRG), Japan*—H Masuda, M Toi, T Ueno.

*Japan Clinical Oncology Group—Breast Cancer Study Group, Japan*—H Iwata, T Shien.

*Japanese Association for Treatment of Breast Cancer with Zoladex, Japan*—S Mitsuyama, Y Nomura, S Ohno.

*Japanese Foundation for Multidisciplinary Treatment of Cancer, Tokyo, Japan*—O Abe, T Ikeda, K Inokuchi, K Kikuchi, K Sawa.

*Kanagawa Breast Oncology Group, Japan*—T Ishikawa, K Narui.

*Kawasaki Medical School, Japan*—H Sonoo.

*Klinikum Bayreuth, Germany*—M Sadoon, A H Tulusan.

*Kobe Breast Cancer Oncology Group, Japan*—N Kohno, K Matsumoto, M Miyashita, S Takao.

*Korean Breast Cancer Study Group (KBCSG), Republic of Korea*—S Y Baek, S A Im, J Jeong, Y S Jung, H A Kim, H J Kim, L S Kim, S Y Kim, M H Lee, W C Noh, K H Park.

*Korean Cancer Study Group (KCSG), Seoul, Republic of Korea*—J-H Ahn, K H Jung.

*Korean Radiation Oncology Group, Seoul (KROG), Republic of Korea*—C-O Suh.

*Krakov Institute of Oncology, Poland*—S Korzeniowski, J Skolyszewski.

*Kumamoto University Group, Japan*—M Ogawa, J Yamashita.

*Leiden University Medical Center, Netherlands*—E Bastiaannet, G J Liefers, C J H van de Velde.

*Leuven Akademisch Ziekenhuis, Gasthuisberg, Belgium*—R Christiaens, P Neven, R Paridaens, W Van den Bogaert.

*Ludwig-Maximilians University, Munich, Germany*—S Braun, H Sommer.

*Marseille Laboratoire de Cancérologie Biologique APM, France*—P Martin, S Romain.

*Medical University Vienna – General Hospital - Department of Obstetrics and Gynaecology and Department of Medicine I, Vienna, Austria*—M Janauer, M Seifert, P Sevelde, C C Zielinski.

*Memorial Sloan-Kettering Cancer Center, New York, NY, USA*—T Hakes, C A Hudis, L Norton, R Wittes.

*Metaxas Memorial Cancer Hospital, Athens, Greece*—P Foroglou, G Giokas, D Kondylis, B Lissaios (deceased).

*Mexican National Medical Center, Mexico City, Mexico*—R de la Huerta, M G Sainz.

*MonarchE trial (international)*—M P Goetz, S Johnston, S Moulder.

*Multicentre Group, Germany*—S Kümmel, M Reinisch.

*National Cancer Center, Goyang, South Korea*—K S Lee, B-H Nam, J Ro.  
*National Cancer Institute, Bethesda, MD, USA*—K Camphausen, D Danforth, A Lichter, M Lippman, D Smart, S Steinberg.  
*National Cancer Institute, Naples, Italy*—A de Matteis, F Perrone.  
*National Cancer Institute of Bari, Italy*—C D'Amico, M Lioce, A Paradiso.  
*National Kyushu Cancer Center, Japan*—Y Nomura, S Ohno.  
*National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA, USA*—S Anderson, H Bandos, H Bear, A Brown (deceased), J Bryant (deceased), R Cecchini, J Costantino, J Dignam, B Fisher, C Geyer, E P Mamounas, S Paik, P Rastogi, C Redmond, E Romond, S Swain, G Tang, M A Torres, L Wickerham, N Wolmark, G Yothers.  
*National Surgical Adjuvant Study Group (N-SAS-BC), Japan*— T Aihara, K Higaki, Y Hozumi, T Iwase, K Iijima, H Mukai, S Ohtani, H Ohtsu, S Saji, H Takei, Y Yanagida.  
*Neo-tAnGo Trial Group, UK*—H Earl, L Hiller, A-L Vallier.  
*Nolvadex Adjuvant Trial Organisation, London, UK*—M Baum, I M Jackson (deceased), M K Palmer.  
*North Central Cancer Treatment Group (NCCTG), Mayo Clinic, Rochester, MN, USA*—A Moreno-Aspitia, J N Ingle, E Perez, V J Suman.  
*North Sweden Breast Cancer Group, Umeå, Sweden*—A Andresson, N O Bengtsson, H Jonsson, M Sund.  
*North-Western British Surgeons, Manchester, UK*—J P Lythgoe, R Swindell.  
*Northwick Park Hospital, London, UK*—M Kissin.  
*Norwegian Breast Cancer Group, Oslo, Norway*—B Erikstein, E Hannisdal, A B Jacobsen, K V Reinertsen, J E Varhaug.  
*Norwegian Radium Hospital, Oslo, Norway*—B Erikstein, S Gundersen, M Hauer-Jensen, H Høst, A B Jacobsen, R Nissen-Meyer.  
*Nottingham City Hospital, UK*—R W Blamey, A K Mitchell, D A L Morgan, J F R Robertson.  
*Nuffield Department of Population Health (NDPH), Oxford, UK (ie, members of the Oxford-based EBCTCG Secretariat)*—G Beake, R Berry, C Boddington, R Bradley, J Braybrooke, J A Burrett, M Clarke, D Cutter, C Davies, L Davies, D Dodwell, F Duane, V Evans, L Gettins, J Godwin, R Gray, R Hills, F Holt, S James, A Kerr, H Liu, Z Liu, E MacKinnon, G Mannu, P McGale, T McHugh, P Morris, M Nakahara, H C Pan, R Peto, S Read, E Straiton, C Taylor, H Taylor, Y Wang, Z Wang.  
*Oita Prefectural Hospital, Japan*—H Ueo.  
*Oncofrance, Paris, France*—M Di Palma, G Mathé (deceased), J L Misset.  
*Ontario Clinical Oncology Group, Hamilton, Canada*—M Levine, K I Pritchard, T Whelan.  
*Osaka City University, Japan*—K Morimoto.  
*Osaka National Hospital, Japan*—K Sawa, Y Takatsuka.  
*Ospedale Policlinico San Martino, Genova, Italy*—D Bedognetti, C Bighin, P Bruzzi, L Del Mastro, B Dozin, S Pastorino, P Pronzato, M R Sertoli.  
*Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford, UK*—E Crossley, A Harris, D Talbot, M Taylor.  
*PACS Study Group, France*—T Bachelot, S Delaloge, T Delozier, J Lemonnier, A-L Martin, S Michiels, H Roché, M Spielmann.  
*Parma Hospital, Italy*—G Cocconi, B di Blasio.  
*Petrov Research Institute of Oncology, St Petersburg, Russia*—V Ivanov, R Paltuev, V Semiglazov.  
*Piedmont Oncology Association, Winston-Salem, NC, USA*—J Brockschmidt, M R Cooper.  
*Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh, India*—B S Yadav.  
*Pretoria University, South Africa*—C I Falkson.  
*ProBONE study group, Marburg, Germany*—P Hadji.  
*Royal Marsden NHS Trust, London and Sutton, UK*—R A'Hern, M Dowsett, A Makris, M Parton, K Pennert, T J Powles, I E Smith, J R Yarnold.  
*SABRE trial group (international)*—G Clack, C Van Poznak.  
*St George Hospital, Sydney, Australia*—L Browne, P Graham.

*St George's Hospital, London, UK*—J C Gazet.  
*St Luke's Hospital, Dublin, Ireland*—N Corcoran.  
*Samuel Oschin Comprehensive Cancer Center, Los Angeles, USA*—A E Giuliano.  
*Sardinia Oncology Hospital A Businico, Cagliari, Sardinia*—N Deshpande, L di Martino.  
*SASIB International Trialists, Cape Town, South Africa*—P Douglas, A Hacking, H Høst, A Lindtner, G Notter.  
*Saskatchewan Cancer Foundation, Regina, Canada*—A J S Bryant, G H Ewing, L A Firth, J L Krushen-Kosloski.  
*Scandinavian Adjuvant Chemotherapy Study Group, Oslo, Norway*—R Nissen-Meyer.  
*Shanghai Jiao Tong University School of Medicine, China*—X Chen, K Shen.  
*South Sweden Breast Cancer Group, Lund, Sweden*—H Anderson, F Killander, P Malmström, L Rydén.  
*South-East Sweden Breast Cancer Group, Linköping, Sweden*—L-G Arnesson, J Carstensen, M Dufmats, H Fohlin, B Nordenskjöld, M Söderberg, M Sundqvist.  
*South-Eastern Cancer Study Group and Alabama Breast Cancer Project, Birmingham, AL, USA*—J T Carpenter.  
*Southampton Oncology Centre, UK*—R I Cutress, G T Royle, P D Simmonds.  
*Southwest Oncology Group, San Antonio, TX, USA*—K Albain, W Barlow, G T Budd, J Gralow, D Hayes, G Hortobagyi, R Jagsi, S Martino, L Pusztai, P Sharma, A Thompson.  
*Stockholm Breast Cancer Study Group, Sweden*—J Bergh, T Bondesson, F Celebioglu, K Dahlberg, T Fornander, T Foukakis, I Fredriksson, J Frisell, E Göransson, M Iiristo, U Johansson, E Lenner, L Löfgren, P Nikolaidis, L Perbeck, S Rotstein, K Sandelin, L Skoog, G Svane, E af Trampe, C Wadström.  
*SUCCESS Study Group, Germany*—T Friedl, W Janni, H Sommer.  
*SweBCG 91 RT trial group, Sweden*—P-O Bendahl, E Holmberg, P Karlsson, F Killander, E Nimeus.  
*Swiss Group for Clinical Cancer Research (SAKK), Bern, and OSAKO, St Gallen, Switzerland*—M Castiglione, A Goldhirsch, R Maibach, H J Senn, B Thürlimann.  
*Tamoxifen Exemestrane Adjuvant Multinational (TEAM) trial*—J M S Bartlett, E Bastiaannet, P Hadji, Y Hozumi, D Rea, C J H van de Velde.  
*TACT Trial Group, London, UK*—P Barrett-Lee, J M Bliss, P Ellis, L Kilburn.  
*Tampere University Hospital, Finland*—K Holli, K Rouhento.  
*Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel Aviv University, Israel*—T Safra.  
*Tel Aviv University, Israel*—H Brenner, A Hercbergs.  
*Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas, TX, USA*—J L Blum.  
*Tokyo Cancer Institute Hospital, Japan*—M Yoshimoto.  
*Toronto-Edmonton Breast Cancer Study Group, Canada*—A H G Paterson, K I Pritchard.  
*Toronto Princess Margaret Hospital, Canada*—A Fyles, J W Meakin, T Panzarella, K I Pritchard.  
*TRIO (formerly Breast Cancer International Research Group, BCIRG)*—V Bee, J Crown, H Fung, J Mackey, M Martin, M Press, D Slamon.  
*Tunis Institut Salah Azaiz, Tunisia*—J Bahi.  
*UCBG, French Breast Cancer Intergroup UNICANCER, France*—S Delaloge, W Jacot, J Lemonnier, A L Martin, M Spielmann.  
*UK Multicentre Cancer Chemotherapy Study Group, London, UK*—M Reid, M Spittle.  
*UK/ANZ DCIS Trial*—H Bishop, N J Bundred, J Cuzick, I O Ellis, I S Fentiman, J F Forbes, S Forsyth, W D George, S E Pinder, I Sestak.  
*UK/Asia Collaborative Breast Cancer Group, London, UK*—G P Deutsch, R Gray, D L W Kwong, V R Pai, R Peto, F Senanayake.  
*Universitätsklinikum Ulm, Germany*—T Friedl, W Janni.  
*University and Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy on behalf of GROCTA trialists*—F Boccardo, A Rubagotti.  
*University College London, UK*—M Baum, S Forsyth, A Hackshaw, J Houghton, J Ledermann, K Monson, JS Tobias.

*University Federico II, Naples, Italy*—C Carlomagno, M De Laurentiis, S De Placido.  
*University Hospitals Leuven, Belgium*—H Wildiers.  
*University of Hull and Lincoln County Hospital, UK*—O Eremin, L G Walker.  
*University Medical Center Schleswig-Holstein, Campus Kiel, Germany*—C Schem.  
*University of Edinburgh, UK*—L Williams.  
*University of Leeds, UK*—R Bell, D Cameron, R E Coleman, D Dodwell, S Hinsley, H C Marshall.  
*University of Michigan, USA*—D Hayes, L J Pierce.  
*University of Padua, Padova, Italy*—S M M Basso, F Lumachi.  
*University of Saarland, Germany*—E Solomayer.  
*University of Sheffield, UK*—R E Coleman, J M Horsman, J Lester, M C Winter.  
*University of Texas MD Anderson Cancer Center, Houston, TX, USA*—A U Buzdar, L Hsu.  
*University of West Indies, Jamaica and Bahamas*—G W Jones.  
*University of Wisconsin, USA*—R R Love.  
*Uppsala-Örebro Breast Cancer Study Group, Sweden*—J Ahlgren, H Garmo, L Holmberg, G Liljegren, H Lindman, F Wärnberg.  
*U.S. Oncology, Houston, USA*—L Asmar, J L Blum, S E Jones, J O'Shaughnessy, N Robert.  
*Warwick Clinical Trials Unit, University of Warwick, UK*—J Dunn, H Earl, L Hiller.  
*Washington University, St Louis, Missouri, USA*—R Aft.  
*West German Study Group (WSG), Germany*—O Gluz, N Harbeck, C Liedtke, U Nitz.  
*West of Scotland Breast Trial Group, Glasgow, UK*—A Litton.  
*West Sweden Breast Cancer Study Group, Gothenburg, Sweden*—J Heiman, E Holmberg, P Karlsson, B K Linderholm, F Wärnberg.  
*Western Cancer Study Group, Torrance, CA, USA*—R T Chlebowski.  
*Würzburg University, Germany*—H Caffier.  
*Z-FAST, ZO-FAST & E-ZO-FAST study groups (international)*—A M Brufsky, R E Coleman, H A Llombart, on behalf of Novartis Pharmaceuticals.  
*ZIPP trial (Cancer Research UK; GIVIO, Italy; South East Sweden, and Stockholm)*—M Baum, T Fornander, A Hackshaw, A Nicolucci, B Nordenskjold, R Sainsbury.

22 January 2024.